Drugs for breast and lung cancer 'should be used TOGETHER to treat a range of tumours'

A study by The Institute of Cancer Research and University College London combined the breast-cancer medication palbociclib with the lung-cancer treatment crizotinib.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

We described myelosuppressive chemotherapy changes by febrile neutropenia (FN) risk category (high, i ntermediate, unclassified), PP-CSF use, and, in the first cycle of myelosuppressive chemotherapy, neutropenia-related hospitalization (ICD-9-CM: 288.0X, first 5 positions). We evaluated hospitalization trends using a logistic regression model with spline curve of calendar year adjusting for baseline characteristics.ResultsAnnual cohorts included 1451 –2114 eligible patients for 1995–2007 and 5272–7603 for 2008–2015. Myelosuppressive chemotherapy use with high/intermediate FN risk increased from 31% ...
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Lactic acidosis, glucose deprivation and hypoxia are conditions frequently found in solid tumors because, among other reasons, tumors switch to Warburg effect and secrete high levels of lactate, which decreases the pH (
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Postmenopausal women with high/increasing ET are at increased risk of breast, ovarian and lung cancer. It is important that clinicians are aware of these risks as TVS is a common investigation. This article is protected by copyright. All rights reserved. PMID: 31614036 [PubMed - as supplied by publisher]
Source: The Ultrasound Review of Obstetrics and Gynecology - Category: Radiology Authors: Tags: Ultrasound Obstet Gynecol Source Type: research
Abstract AP-1 is a dimeric complex that is composed of JUN, FOS, ATF and MAF protein families. FOS-related antigen 1 (FRA1) which encoded by FOSL1 gene, belongs to the FOS protein family, and mainly forms an AP-1 complex with the protein of the JUN family to exert an effect. Regulation of FRA1 occurs at levels of transcription and post-translational modification, and phosphorylation is the major post-translational modification. FRA1 is mainly regulated by the mitogen-activated protein kinases signaling pathway and is degraded by ubiquitin-independent proteasomes. FRA1 can affect biological functions, such as tumor...
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Tags: Mol Biol Rep Source Type: research
ConclusionsTaselisib in combination with a taxane has a challenging safety profile. Despite evidence of antitumor activity, the benefit –risk profile was deemed not advantageous. Further development is not planned.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Liposomal drug delivery system of LPV has potential to deliver skin to the systemic circulation and useful for treating cancer. PMID: 31593534 [PubMed - as supplied by publisher]
Source: Infectious Disorders Drug Targets - Category: Infectious Diseases Authors: Tags: Infect Disord Drug Targets Source Type: research
Abstract Coronin-3 (coronin-1C), a homotrimer F-actin-binding protein, has been reported to be important for metastasis in several types of cancers such as lung cancer, gastric cancer, and breast cancer. Here, we present an investigation of the expression and function of coronin-3 in renal cell cancer for the first time. We also confirmed that miR-26 directly targets coronin-3 and down-regulates its expression by western blot assay and dual-luciferase reporter system. The results of MTT and colony formation assay showed that miR-26 suppressed cell proliferation. Wound healing and transwell assay revealed that miR-...
Source: Molecular and Cellular Biochemistry - Category: Biochemistry Authors: Tags: Mol Cell Biochem Source Type: research
ConclusionAlthough LM arising from gynecological cancers is considered rare, identification of LM may be important to predict prognosis and develop new therapeutic strategies.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIn conclusion, this meta-analysis of randomized, controlled phase II trials do not support clinical benefits of metformin added to systemic anticancer therapy in patients with advanced or metastatic cancer. However, further investigations including well-designed phase III trials are needed to resolve the issues (dose of metformin, treatment setting, particular cancer type, or immunomodulatory effect) on the addition of metformin to systemic anticancer therapy.Legal entity responsible for the studyJung Han Kim.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThere was limited intracranial clinical activity for abemaciclib monotherapy in NSCLC and MEL pts in this study; OIRR and short median PFS suggest that no further studies for abemaciclib monotherapy are warranted in this pt population.Clinical trial identificationNCT02308020.Editorial acknowledgementMedical writing assistance was provided by Kristi Gruver, employee of Eli Lilly and Company.Legal entity responsible for the studyEli Lilly and Company.FundingEli Lilly and Company.DisclosureE. Le Rhun: Advisory / Consultancy, Research grant / Funding (institution), Oscar Lambert Center, Lille, FR: Mundipharma; Resea...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Lung Cancer | Study